Serum nitric oxide metabolites in subjects with metabolic syndrome

Clinical Biochemistry

Volumn 41, Issue 16-17, 2008, Pages 1342-1347

  Zahedi Asl, Saleh ^a   Ghasemi, Asghar ^a   Azizi, Fereidoun ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Metabolic syndrome; Nitric oxide; Type 2 diabetes mellitus

Indexed keywords

HIGH DENSITY LIPOPROTEIN; NITRIC OXIDE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; MALE; METABOLIC SYNDROME X; METABOLITE; POPULATION RESEARCH; PRIORITY JOURNAL; SEX DIFFERENCE; WAIST CIRCUMFERENCE;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CONFIDENCE INTERVALS; DIABETES COMPLICATIONS; FEMALE; HUMANS; IRAN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NITRATES; NITRIC OXIDE; NITRITES; RISK FACTORS;

EID: 55049122402     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2008.08.076     Document Type: Article

References (33)

1. Yoon S., Moon J., Shin C., Kim E., Jo S.A., and Jo I. Smoking status-dependent association of the 27-bp repeat polymorphism in intron 4 of endothelial nitric oxide synthase gene with plasma nitric oxide concentrations. Clinica. Chimica. Acta 324 (2002) 113-120
2. Dudzinski D.M., Igarashi J., Greif D., and Michel T. The regulation and pharmacology of endothelial nitric oxide synthase. Annu. Rev. Pharmacol. Toxicol. 46 (2006) 235-276
3. Ding Y., Vaziri N.D., Coulson R., Kamanna V.S., and Roh D.D. Effects of simulated hyperglycemia, insulin, and glucagon on endothelial nitric oxide synthase expression. Am. J. Physiol. Endocrinol. Metab. 279 (2000) E11-17
4. Jansson P.A. Endothelial dysfunction in insulin resistance and type 2 diabetes. J. Intern. Med. 262 (2007) 173-183
5. Kim J.A., Montagnani M., Koh K.K., and Quon M.J. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 113 (2006) 1888-1904
6. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97.
7. x level with clustering of metabolic syndrome components in middle-aged and elderly general populations in Japan. Environ. Health Prev. Med. 13 (2008) 36-42
8. Maejima K., Nakano S., Himeno M., et al. Increased basal levels of plasma nitric oxide in Type 2 diabetic subjects. Relationship to microvascular complications. J. Diabetes Complications 15 (2001) 135-143
9. Perreault M., and Marette A. Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat. Med. 7 (2001) 1138-1143
10. Colasanti M., and Suzuki H. The dual personality of NO. Trends Pharmacol. Sci. 21 (2000) 249-252
11. Dallaire P., and Marette A. Obesity-linked insulin resistance: is nitric oxide the missing link?. Can. J. Diabetes 28 (2004) 59-66
12. Moshage H., Kok B., Huizenga J.R., and Jansen P.L. Nitrite and nitrate determinations in plasma: a critical evaluation. Clin. Chem. 41 (1995) 892-896
13. Miranda K.M., Espey M.G., and Wink D.A. A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric. Oxide. 5 (2001) 62-71
14. Romitelli F., Santini S.A., Chierici E., et al. Comparison of nitrite/nitrate concentration in human plasma and serum samples measured by the enzymatic batch Griess assay, ion-pairing HPLC and ion-trap GC-MS: the importance of a correct removal of proteins in the Griess assay. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 851 (2007) 257-267
15. Kagota S., Yamaguchi Y., Tanaka N., et al. Disturbances in nitric oxide/cyclic guanosine monophosphate system in SHR/NDmcr-cp rats, a model of metabolic syndrome. Life. Sci. 78 (2006) 1187-1196
16. Ellis G., Adatia I., Yazdanpanah M., and Makela S.K. Nitrite and nitrate analyses: a clinical biochemistry perspective. Clin. Biochem. 31 (1998) 195-220
17. Azizi F., Rahmani M., Emami H., et al. Cardiovascular risk factors in an Iranian urban population: Tehran lipid and glucose study (phase 1). Soz. Praventivmed. 47 (2002) 408-426
18. Ghasemi A., Hedayati M., and Biabani H. Protein precipitation methods evaluated for determination of serum nitric oxide end products by the Griess assay. JMSR 2 (2007) 43-46
19. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20 (1997) 1183-1197
20. Behr-Roussel D., Rupin A., Simonet S., et al. Effect of chronic treatment with the inducible nitric oxide synthase inhibitor N-iminoethyl-l-lysine or with l-arginine on progression of coronary and aortic atherosclerosis in hypercholesterolemic rabbits. Circulation 102 (2000) 1033-1038
21. Zhou Y.T., Grayburn P., Karim A., et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 1784-1789
22. Schwartz D., Mendonca M., Schwartz I., et al. Inhibition of constitutive nitric oxide synthase (NOS) by nitric oxide generated by inducible NOS after lipopolysaccharide administration provokes renal dysfunction in rats. J. Clin. Invest. 100 (1997) 439-448
23. Shankar R.R., Wu Y., Shen H.Q., Zhu J.S., and Baron A.D. Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance. Diabetes 49 (2000) 684-687
24. Scherrer U., and Sartori C. Defective nitric oxide synthesis: a link between metabolic insulin resistance, sympathetic overactivity and cardiovascular morbidity. Eur. J. Endocrinol. 142 (2000) 315-323
25. Cui R., Iso H., Pi J., et al. Metabolic syndrome and urinary cGMP excretion in general population. Atherosclerosis 190 (2007) 423-428
26. Chien W.Y., Yang K.D., Eng H.L., et al. Increased plasma concentration of nitric oxide in type 2 diabetes but not in nondiabetic individuals with insulin resistance. Diabetes Metab. 31 (2005) 63-68
27. Honing M.L., Morrison P.J., Banga J.D., Stroes E.S., and Rabelink T.J. Nitric oxide availability in diabetes mellitus. Diabetes Metab. Rev. 14 (1998) 241-249
28. Shimabukuro M., Ohneda M., Lee Y., and Unger R.H. Role of nitric oxide in obesity-induced beta cell disease. J. Clin. Invest. 100 (1997) 290-295
29. Himeno M., Ishibashi T., Nakano S., et al. A practical procedure for achieving a steady state of NOx concentration in plasma: with special reference to the NOx content of Japanese daily food. Tohoku. J. Exp. Med. 199 (2003) 95-110
30. Node K., Kitakaze M., Yoshikawa H., Kosaka H., and Hori M. Reduced plasma concentrations of nitrogen oxide in individuals with essential hypertension. Hypertension 30 (1997) 405-408
31. Bryan N.S., and Grisham M.B. Methods to detect nitric oxide and its metabolites in biological samples. Free Radic. Biol. Med. 43 (2007) 645-657
32. Grattagliano I., Palmieri V.O., Portincasa P., Moschetta A., and Palasciano G. Oxidative stress-induced risk factors associated with the metabolic syndrome: a unifying hypothesis. J. Nutr. Biochem. 19 (2008) 491-504
33. Maeda S., Miyauchi T., Kakiyama T., et al. Effects of exercise training of 8 weeks and detraining on plasma levels of endothelium-derived factors, endothelin-1 and nitric oxide, in healthy young humans. Life Sci. 69 (2001) 1005-1016